Science News
from research organizations

Predicting outcome for high-dose IL-2 therapy in cancer patients

Date:
December 2, 2013
Source:
Journal of Clinical Investigation
Summary:
Previous studies indicate that regulatory T cell (Treg) populations increase in patients undergoing HD IL-2 therapy. Researchers now report on their study that performed an in depth analysis of Treg populations in melanoma patients undergoing HD IL-2 therapy.
Share:
       
FULL STORY

One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission; however, use of HD IL-2 therapy is limited due to the toxic effects associated with treatment. Because HD IL-2-associated toxicity is severe, it would be beneficial for clinicians to determine if a patient would respond favorably to this treatment prior to side effect onset.

Previous studies indicate that regulatory T cell (Treg) populations increase in patients undergoing HD IL-2 therapy, and in this issue of the Journal of Clinical Investigation, Lazlo Radvanyi and colleagues at M.D. Anderson Cancer Center performed an in depth analysis of Treg populations in melanoma patients undergoing HD IL-2 therapy. The authors identified a distinct population of Treg cells that expressed the inducible T cell costimulator (ICOS) that was highly proliferative following the first cycle of HD IL-2.

Furthermore, melanoma patients with greater levels of ICOS+ Tregs in response to HD IL-2 had better clinical outcomes, suggesting that this Treg population may be useful to predict which patients would benefit from HD IL-2.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Geok Choo Sim, Natalia Martin-Orozco, Lei Jin, Yan Yang, Sheng Wu, Edwina Washington, Deborah Sanders, Carol Lacey, Yijun Wang, Luis Vence, Patrick Hwu, Laszlo Radvanyi. IL-2 therapy promotes suppressive ICOS Treg expansion in melanoma patients. Journal of Clinical Investigation, 2013; DOI: 10.1172/JCI46266

Cite This Page:

Journal of Clinical Investigation. "Predicting outcome for high-dose IL-2 therapy in cancer patients." ScienceDaily. ScienceDaily, 2 December 2013. <www.sciencedaily.com/releases/2013/12/131202121449.htm>.
Journal of Clinical Investigation. (2013, December 2). Predicting outcome for high-dose IL-2 therapy in cancer patients. ScienceDaily. Retrieved May 30, 2015 from www.sciencedaily.com/releases/2013/12/131202121449.htm
Journal of Clinical Investigation. "Predicting outcome for high-dose IL-2 therapy in cancer patients." ScienceDaily. www.sciencedaily.com/releases/2013/12/131202121449.htm (accessed May 30, 2015).

Share This Page: